Lexotan

Patient Information Leaflet

Warning! Keep this leaflet! Information on the immediate packaging is in a foreign language.
Lexotan (Lexotanil), 3 mg, tablets
Bromazepamum
Lexotan and Lexotanil are different brand names for the same medicine.
Please read all of this leaflet carefully before taking this medicine because it contains
important information for you.

• Keep this leaflet so that you can read it again if necessary.
• If you have any questions, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not share it with others. This medicine may harm another person, even if their symptoms are the same.
• If you experience any adverse effects, including any adverse effects not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of contents of the leaflet

1. What Lexotan is and what it is used for
2. Important information before taking Lexotan
3. How to take Lexotan
4. Possible side effects
5. How to store Lexotan
6. Contents of the pack and other information

1. What Lexotan is and what it is used for

Lexotan contains bromazepam, which is an anxiolytic medicine belonging to the group of benzodiazepines.
Lexotan is indicated for pharmacological treatment of:

• generalized anxiety disorders
• autonomic dysfunctions presenting in somatic form, including skin, gastrointestinal, cardiovascular, and urogenital symptoms
• anxiety states occurring in the course of chronic organic diseases of the central nervous system
• post-traumatic stress disorders with anxiety symptoms
• adjustment disorders.

2. Important information before using Lexotan

When not to use Lexotan:

• if the patient is allergic to benzodiazepines or any of the other ingredients of this medicine (listed in section 6)
• if the patient has severe respiratory insufficiency
• if the patient has severe hepatic insufficiency (benzodiazepines are not indicated for the treatment of patients with severe liver impairment due to the risk of brain damage)
• if the patient has muscle weakness (myasthenia gravis)
• if the patient has sleep apnoea syndrome.

Warnings and precautions

The patient should remain under medical supervision throughout the duration of treatment – at the beginning of treatment to determine the minimum effective dose and dosing frequency, and during treatment to prevent overdose.

Memory impairment

Benzodiazepines may cause anterograde amnesia. This condition most commonly occurs several hours after taking the medicine. To reduce the risk of anterograde amnesia, the patient should ensure uninterrupted sleep for several hours. Amnesic effects may be associated with abnormal behaviour.

Psychological reactions

When using benzodiazepines, reactions such as anxiety, excitement, irritability, aggression, restlessness, delusions concerning the external environment or one's own state, outbursts of anger, nightmares, hallucinations, psychoses, unusual behaviour and other undesirable behaviours may occur. If such symptoms occur, contact a doctor immediately.

The above-mentioned symptoms are more likely to occur in children and elderly patients.

Duration of treatment

Treatment duration is limited (should not exceed 8–12 weeks), and the dose should be gradually reduced under medical supervision. During discontinuation of the drug, a rebound phenomenon may occur (see section 3, "Discontinuing treatment with Lexotan").

Alcohol consumption or use of medicines that depress the central nervous system

During treatment with Lexotan, alcohol should not be consumed and medicines that depress central nervous system function should not be taken.

Alcohol may intensify the effect of Lexotan and cause severe sedation, as well as respiratory or circulatory depression, which may lead to coma or death.

Tolerance

Repeated administration of Lexotan over a prolonged period may lead to reduced effectiveness.

During benzodiazepine treatment, switching from one benzodiazepine to another with a significantly shorter half-life may lead to withdrawal symptoms.

Benzodiazepines should not be used as the sole treatment for depression or anxiety states associated with depression (in such conditions, suicidal tendencies may be increased).

Benzodiazepines should not be used as first-line treatment for psychotic disorders.

Due to the muscle-relaxant effect of the medicine, there is a risk of falls and hip fractures, particularly in elderly patients who get up at night.

History of alcohol, drug or medication abuse

The medicine should be used with particular caution and strictly according to the doctor's instructions.

Dependence on the medicine

Taking medicines from the benzodiazepine group, including Lexotan, or similarly acting medicines, may lead to the development of both physical and psychological dependence. The risk of dependence increases with dose and duration of treatment. The risk is also higher in patients with a history of alcohol, drug or medication abuse, and in patients with personality disorders.

Warnings regarding specific patient groups

Particular care should be taken in patients with chronic respiratory insufficiency due to the risk of respiratory disturbances.

Extreme caution should be exercised in patients with mild or moderate liver impairment.

Benzodiazepines should not be given to children without careful assessment of the justification for their use; treatment duration should be as short as possible, and the dose should be individually adjusted.

Elderly patients should receive a reduced dose.

Pregnancy and breastfeeding

Before taking any medicine, consult a doctor or pharmacist.

Pregnancy

The safety of bromazepam use in pregnant women has not been definitively established. Although there are no clinical data indicating significant congenital malformations in the fetus due to benzodiazepine use during the first trimester of pregnancy, some epidemiological studies have shown an increased risk of oral clefts.

Therefore, bromazepam should not be used during pregnancy unless strictly indicated and under strict adherence to the prescribed dosing regimen.

Patients should consult their doctor about discontinuing treatment if they are planning to become pregnant or suspect they are pregnant.

Administration of bromazepam during the third trimester of pregnancy and during delivery is permitted only in cases of absolute necessity, as adverse effects in newborns may be expected, such as hypothermia (lowered body temperature), reduced muscle tone leading to sucking difficulties (resulting in poor weight gain), and moderate respiratory depression or apnoea. Additionally, withdrawal symptoms in the newborn, manifesting as excessive irritability, restlessness and tremors, have been observed.

In children of mothers who have taken benzodiazepines long-term during the final stages of pregnancy, physical dependence on the drug and risk of withdrawal symptoms after birth may occur.

Breastfeeding

Benzodiazepines pass into breast milk; therefore, women who are breastfeeding should not use Lexotan.

Driving and operating machinery

Do not drive motor vehicles or operate machinery, as Lexotan may cause excessive sedation and amnesia, impair concentration and muscle function. In cases of sleep deprivation, the likelihood of reduced alertness may increase. This effect may be particularly intensified if the patient has also consumed alcohol.

Lexotan with other medicines

Inform the doctor about all medicines currently or recently taken, as well as any medicines the patient plans to use.

Concomitant use of Lexotan with any medicines that depress the central nervous system (e.g. antidepressants, hypnotics, opioid analgesics, neuroleptics, anxiolytics and sedatives, anticonvulsants, sedative antihistamines) and alcohol may enhance the sedative effect of the medicine and increase its respiratory and circulatory depressant effects.

When opioid analgesics are used concomitantly, a state of euphoria may occur, increasing the risk of psychological dependence.

Substances that inhibit the activity of certain liver enzymes may affect benzodiazepines metabolized by these enzymes. Concomitant administration of Lexotan with cimetidine, fluvoxamine, or (probably) propranolol may result in stronger or prolonged effects.

Lexotan contains monohydrate lactose. If the patient has previously been diagnosed with intolerance to certain sugars, the patient should consult a doctor before taking Lexotan.

3. How to use Lexotan

This medicine should always be used as directed by the physician. In case of doubt, consult your
doctor.
Lexotan is available in doses of 3 mg and 6 mg.
In all cases, Lexotan should be used under medical supervision.
Typical dosage
Average doses for outpatients: 1.5 mg to 3 mg three times daily.
Severe cases, especially in hospital treatment: 6 mg to 12 mg two or three times daily.
The physician should treat these dosage recommendations as general guidelines and adjust the dose
individually for each patient. Outpatient treatment should begin with low doses, gradually increasing
them to the optimal level. Treatment should last as short as possible.
Patients should visit their doctor regularly to assess whether continued use of the medicine is
necessary, especially when disease symptoms are no longer observed. The total duration of therapy
should not exceed 8 to 12 weeks, including the tapering-off period.
In some cases, therapy may last longer, provided a specialist evaluation of the patient's condition
has been performed by the physician.
Elderly patients and patients with impaired liver function require lower doses.
If the effect of Lexotan seems too strong or too weak, consult your doctor.
Use of a higher than recommended dose of Lexotan
If a higher than recommended dose is taken, contact your doctor immediately.
The doctor will decide on further management.
Common symptoms of benzodiazepine overdose include: drowsiness, impaired coordination, speech
disturbances, and nystagmus.
Overdose with Lexotan rarely threatens life when the drug is taken alone. However, it may lead to
loss of reflexes, apnea, hypotension, cardiorespiratory depression, and coma. Coma, if it occurs,
usually lasts several hours but may recur and deepen, especially in elderly individuals. Respiratory
depression symptoms are more severe in patients with coexisting respiratory disorders.
Benzodiazepines enhance the effects of other central nervous system depressants (including alcohol).
Missed dose of Lexotan
Do not use a double dose to make up for a missed dose.
Discontinuation of Lexotan
If physical dependence has developed, withdrawal symptoms (withdrawal syndrome) may occur
after stopping treatment.
These may include: headache, diarrhea, muscle pain, increased anxiety, tension, restlessness,
disorientation, and irritability. In severe cases, the following symptoms may occur:
distorted perception of surroundings (derealization), disturbances in sense of self (depersonalization),
hypersensitivity to sound, numbness and tingling in limbs, hypersensitivity to light, noise, and touch,
hallucinations, or seizures.
After discontinuation, rebound anxiety may occur—a transient syndrome in which symptoms that
led to the use of Lexotan return in an intensified form. Other reactions may also occur, such as:
mood changes, anxiety, sleep disturbances, and restlessness.
Since the risk of withdrawal syndrome and rebound phenomenon is greater with abrupt discontinuation,
it is recommended to gradually reduce the dose of Lexotan.
If you have any further doubts regarding the use of this medicine, consult your doctor.

4. Possible adverse effects

Like all medicines, Lexotan may cause adverse effects, although not everyone experiences them.
The adverse effects listed below occurred with an unknown frequency (cannot be estimated
from available data):

• hypersensitivity (allergy), anaphylactic shock, angioedema
• confusion, disorientation, emotional disturbances and mood disturbances – mainly at the beginning of treatment and usually subsiding during treatment
• disturbances in libido
• drug dependence, drug abuse, withdrawal syndrome
• depression
• paradoxical reactions such as anxiety, agitation, irritability, aggression, delusions, anger, nightmares, hallucinations, psychosis, unusual behaviour, restlessness, anxiety, abnormal dreams, excessive activity and other behavioural disturbances – higher likelihood of such reactions in children and elderly patients
• anterograde amnesia
• memory impairment
• drowsiness, headache, dizziness, reduced alertness, problems with motor coordination and balance – mainly at the beginning of treatment and usually subsiding during treatment
• double vision – mainly at the beginning of treatment and usually subsiding during treatment
• heart failure, including cardiac arrest
• reduced depth and frequency of respiration
• nausea, vomiting – mainly at the beginning of treatment and usually subsiding during treatment
• constipation
• rash, itching, urticaria
• decreased muscle strength – mainly at the beginning of treatment and usually subsiding during treatment
• urinary retention
• fatigue – mainly at the beginning of treatment and usually subsiding during treatment
• falls, fractures – risk is increased in patients concurrently using sedatives (including alcoholic beverages) and in elderly patients.

Dependence:
Prolonged use of the medicine (even at therapeutic doses) may lead to the development of
psychological and physical dependence. Discontinuation of treatment may result in withdrawal
symptoms or rebound anxiety (worsening of disease symptoms – see "Discontinuation of Lexotan treatment").
Cases of benzodiazepine abuse have been reported.
Reporting of adverse effects
If any adverse effects occur, including any adverse effects not listed
in this leaflet, inform your doctor or pharmacist. Adverse effects can be reported
directly to the Department of Monitoring Adverse Drug Reactions of the Office for Medicinal Products, Medical Devices and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl.
Reporting adverse effects helps to gather more information on the safety of the medicine.

5. How to store Lexotan

Keep this medicine out of sight and reach of children.
Do not store above 30°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the packaging and other information

What Lexotan contains

• The active substance is bromazepam (Bromazepamum). One tablet contains 3 mg of bromazepam.
• The other ingredients are: microcrystalline cellulose, magnesium stearate, talc, lactose monohydrate, iron oxide red (E 172).

What Lexotan looks like and contents of the pack
Lexotan is in the form of tablets.
The pack contains 30 tablets in PVC blisters placed in a cardboard box.
For more detailed information, please contact the marketing authorisation holder or the parallel importer.
Marketing authorisation holder in Austria, country of export:
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Manufacturer:
Delpharm Milano S.r.l.
Via Carnevale, 1
20090, Segrate (MI)
Italy
Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Repackaged in:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorisation number in Austria, country of export: 16.224
Parallel import authorisation number: 236/22